Provided herein are immunoconjugate fusion proteins for the treatment of disorders associated with neovascularization (e.g. tumor-associated neovascularization, e.g., ocular melanoma), and symptoms associated with the same. The methods comprise administering the patient in one or more dosing sessions, a composition comprising an effective amount of any one or more of the immunoconjugate proteins described herein, wherein each immunoconjugate comprises at least one mutated Factor VIIa (FVIIa) protein conjugated to an immunoglobulin Ig Fc dimer.
